extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 
 At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+Sarcopenic obesity risk from muscle loss + discontinuation may create NEW healthcare costs (falls, fractures, disability care) that offset cardiovascular and metabolic savings, particularly in the Medicare-age population. If the most common outcome is weight cycling with net muscle loss rather than sustained metabolic benefit, the population-level health effect could be negative for elderly patients.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+The discontinuation problem is compounded by the weight cycling mechanism: patients who stop GLP-1s regain fat preferentially while muscle is NOT regained, creating sarcopenic obesity. This means discontinuation doesn't just eliminate metabolic benefits—it actively worsens body composition relative to baseline, especially in elderly populations already at sarcopenia risk.
+
 ---
 
 Relevant Notes:

entities/internet-finance/futardio.md

@@ -54,6 +54,7 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
 - **2026-02-03** — Hurupay fundraise launched targeting $3M, closed Feb 7 at $2M (67% of target) in refunding status
 - **2026-03-05** — Seyf AI-native wallet launch: raised $200 against $300,000 target, refunded (99.93% shortfall)
 - **2026-03-06** — LobsterFutarchy launch raised $1,183 against $500,000 target, closed in refunding status after one day
+- **2024-08-28** — MetaDAO futarchy proposal to develop futardio (memecoin launchpad with futarchy governance) failed. Proposal would have allocated $100k grant over 6 months to development team. Market rejected the concept, likely due to reputational concerns about associating futarchy with memecoins.
 ## Competitive Position
 - **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
 - **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."

inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json

@@ -0,0 +1,26 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 3,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16",
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d",
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category"
+    ],
+    "rejections": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md

@@ -7,9 +7,13 @@ date: 2025-07-01
 domain: health
 secondary_domains: []
 format: review
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,12 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m
 EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect
 
 flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"]
+
+
+## Key Facts
+- 15-40% of total weight lost on GLP-1s is lean body mass (not fat)
+- Some analyses suggest up to 60% lean mass loss in certain patients
+- Natural aging reduces skeletal muscle mass by 12-16%
+- Sarcopenic obesity prevalence: 10-20% of older adults
+- 64.8% of GLP-1 patients discontinue within 1 year
+- Next-generation GLP-1 therapies aim to improve muscle preservation per ADA